CD19 and diffuse large B-cell lymphoma: (46), conducted a multi-center retrospective cohort study comparing ibrutinib combined with CD19-targeted CAR-T cell immunotherapy (n=16) versus CAR-T monotherapy (n=10) in patients with R/R DLBCL.